MiR-192 Confers Cisplatin Resistance by Targeting Bim in Lung Cancer

MiR-192 Confers Cisplatin Resistance by Targeting Bim in Lung Cancer

Background and objective Cisplatin is the first-line drug for the chemotherapy of non-small cell lung cancer (NSCLC), but the acquired chemoresistance restricted the effect of its treatment. The aim of this study is to validate the miRNAs related to the Cisplatin resistance in lung cancer and elucid...

Full description

Bibliographic Details
Main Authors: Fang ZHANG, Yang LI, Heng WU, Kang QI, Jiacong YOU, Xuebing LI, Lingling ZU, Zhenhua PAN, Yuli WANG, Yongwen LI, Ying LI, Min WANG, Wang SHEN, Qinghua ZHOU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2014-05-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
miRNA microarray
RT-PCR
miR-192
Bim
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2014.05.04

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2014.05.04

Similar Items